| | Author | Treatment | N | Patient type | SD | PR | CR | ORR | TTP | CB | PFS | OS |
| | Chura, 2007 | Bev 10 mg/kg q14d
CP 50 mg qd po | 15 | Pretreated,
recurrent | 3
(20%) | 6
(40%) | 2
(13.3%) | 53% | - | - | - | - |
| | Gordinier, 2007 | Standard regimens | 18 | Pretreated, ovarian or
primary peritoneal | 60% | 6.7% | - | - | - | - | 3.7 m | - | | Thalidomide 200 mg qd | 18 | 53.8% | 5% | 3.8 m | | None | 4 | ? | ? | ? |
| | Downs, 2008 | Topotecan 1.25 mg/ m2days 1-5, q21d | 30 | Recurrent, epithelial,
platinum refractory | - | 17% | 30% | 47% | - | - | - | 19 m | Thalidomide 200 mg qd increasing to maximum tolerated
Vs. | Vs. | | Vs. | Vs. | Vs. | | | | Vs. | | Topotecan 1.25 mg/ m2 days 1-5, q21d | 39 | - | 3% | 18% | 21% | - | - | - | 15 m |
| | Garcia, 2008 | Bev 10 mg/kg q14d
CP 50 mg qd po | 17 | Recurrent,
platinum refractory | - | 17
(24%) | - | - | 7.2 m | - | 6 m
(56%) | 16.9 m |
| | Jurado, 2008 | Bev 10 mg/kg q14d
CP 50 mg qd po | 9 | Recurrent, platinum
refractory | 2
(22%) | 2
(22%) | 2
(22%) | 4
(44%) | 5.5 m | - | 6 m
(33%) | - |
| | Hurteau, 2010 | Thalidomide 200 mg qd increasing to maximum tolerated or 400 mg
vs
Tamoxifen 20 mg qd po for 1 year | 138 | Stage III/IV, disease free after 1st line, | Closed early, interim analysis showed thalidomide was inferior to tamoxifen |
| | Sanchez-Munoz, 2010 | Bev 10 mg/kg q14d
CP 50 mg qd po | 38 | Pretreated, recurrent | 3
(8.1%)
(6 w) | 12
(32.4%) | 3
(8.1%) | - | - | - | 4.5 m | 10.7 m |
| | Legge, 2011 | Carboplatin AUC5, q28d
Celecoxib 400 mg qd | 45 | Pretreated, recurrent | | 10 | 3 | 29% | - | - | 5 m | 13 m |
| | McGonigle, 2011 | Bev 10 mg/kg days 1, 13 q28d
Topotecan 4 mg/ m2 days 1, 8, 15 q28d | 40 | Platinum resistant,
ovarian / peritoneal / fallopian | 14
(35%) | 10
(25%) | - | - | - | - | 7.8 m | 16.6 m |
| | Ramasubbaiah, 2011 | Sorafenib 400 mg qd
Topotecan 3.5 mg/ m2 days 1, 8, 15 q28d | 14 | Platinum
resistant, | 14
(46.7%) | 5
(16.7%) | - | - | - | - | - | - |
| | Kucukoner, 2012 | Etoposide 50 mg qd po days 1-14 q28d | 51 | Platinum resistant, | 25.5% | 17.6% | | | | | 3.9 m | 16.4 m |
| | Barber, 2013 | Bev 10 mg/kg q14d
CP 50 mg qd po | 66 | Pretreated, recurrent | 15
(22.7%) | 21
(31.8%) | 7
(10.6%) | 42.4% | | | 5 m
responders) | 20 m
responders) |
| | Ferrandina, 2014 ® | CP 50 mg qd po | 54 | Platinum resistant/sensitive | - | 11
(20.4%) | - | 20.4% | | | 4 m | 13 m |
| | Bhattacharyya, 2015 | CP 50 mg qd po
TMZ 20 mg bid days 1-14, q21d | 55 | Platinum resistant, | | 24 | N/A | 44% | | | 5.9 m | 10.1 m |
| Roque, 2015
® | Ixabepilone 16-20 mg/ m2 days 1, 8, 15, q28d | 8/3 | Uterine/Ovarian-fallopian-peritoneal | - | - | - | 41.7% | - | - | 3.0 m/- | - | | Vs | | | | | | | | | 9.6 m | Ixabepilone 16-20 mg/ m2 days 1, 8, 15, q28d
Bev 10 mg/kg q14d | 16/33 | - | - | - | - | - | - | 6.5 m/ - | - |
|
|
